2004 Annual Meeting | Clinical Approach to Muscle Disease

Date Saturday 05/01/04

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Carlayne E. Jackson, MD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Upon completion:
Participants should be able to appreciate how the advances in our understanding of the molecular pathogenesis of muscle diseases can be applied clinically to enhance our diagnostic abilities. More importantly, the participant should understand how these advances are leading to more effective management and treatment of these challenging conditions.

The American Board of Psychiatry and Neurology has reviewed Clinical Approach to Muscle Disease and has approved this product as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
09:00 AM - 09:45 AM		Myopathy Made Ridiculously Simple: A Pattern Recognition Approach Carlayne E. Jackson, MD, FAAN
09:45 AM - 10:45 AM		Approach to Diagnostic Testing of the Myopathy Patient Matthew P. Wicklund, MD, FAAN
10:45 AM - 11:00 AM		Break
11:00 AM - 11:55 AM		Approach to the Management of Cardiac, Pulmonary, and Muscle Complications of Myopathies David S. Saperstein, MD
11:55 AM - 12:45 PM		Current and Emerging Treatments in Myopathy John T. Kissel, MD, FAAN

Faculty Disclosures
John T. Kissel, MD, FAAN	Dr. Kissel has nothing to disclose.
Carlayne E. Jackson, MD, FAAN	Dr. Jackson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe Pharma America. Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for AAN. The institution of Dr. Jackson has received research support from NIH. The institution of Dr. Jackson has received research support from Massachussetts General Hospital.
David S. Saperstein, MD	No disclosure on file
Matthew P. Wicklund, MD, FAAN	Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus Therapeutics. Dr. Wicklund has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta Therapeutics. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Spark Therapeutics. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ultragenyx. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex Pharmaceuticals. The institution of Dr. Wicklund has received research support from Orphazyme. The institution of Dr. Wicklund has received research support from Muscular Dystrophy Association. The institution of Dr. Wicklund has received research support from Coalition to Cure Calpain 3. The institution of Dr. Wicklund has received research support from Sarepta Therapeutics. The institution of Dr. Wicklund has received research support from ML Bio. The institution of Dr. Wicklund has received research support from Alexion. The institution of Dr. Wicklund has received research support from Acceleron. The institution of Dr. Wicklund has received research support from Edgewise. The institution of Dr. Wicklund has received research support from Fulcrum. The institution of Dr. Wicklund has received research support from Roche-Genentech. The institution of Dr. Wicklund has received research support from Avidity. Dr. Wicklund has received research support from Harmony Bioscience.

��ɫ��

��ɫ��